Actina

Actina is building OcuDepth, a precision AI platform for chronic eye disease, starting with glaucoma and expanding into age-related macular degeneration and diabetic retinopathy. We believe ophthalmology still relies too heavily on interpreting individual tests, even though each exam is only a partial and noisy observation of the eye's underlying disease state. At Actina, our aim is to go beyond diagnosis and automation by augmenting clinicians beyond what they can reliably integrate unaided across time and modalities. OcuDepth combines OCT, visual fields, fundus imaging, intraocular pressure, demographics, treatment history, and eventually genomics to estimate true biological state, quantify uncertainty, and track progression over time. By decoding structure-function relationships, it helps detect meaningful change earlier, with fewer tests, and better understand where disease is heading. We are initially focused on pharma, CROs, and research networks, where better progression measurement can improve endpoint reliability, cohort enrichment, treatment-effect measurement, and longitudinal monitoring. Over time, we aim to bring that same trial-grade measurement into routine care, helping turn ophthalmology into a more continuous, evidence-generating system. Our long-term vision is to shift the field from test-based medicine to state-based medicine, where chronic eye disease is understood continuously, measured more faithfully, and managed earlier and more intelligently. Beyond ophthalmology, we see the eye as one of medicine's richest accessible windows into systemic, vascular, metabolic, and neurodegenerative biology. Actina's endgame is to turn that window into a high-resolution platform for measuring disease, therapeutic response, and human health over time. At Actina we help patients preserve their vision while partners deliver theirs.